Labcorp Announces Acquisition of Select Assets of BioReference Health's Diagnostics Business

Transaction to enhance Labcorp's laboratory services network  and expand access to the company's high-quality clinical laboratory services BURLINGTON, N.C. and MIAMI , March 28, 2024 /PRNewswire/ --  Labcorp  (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO

Supporting customer success through powerful sample logistics and a global central lab network

A leading Japanese pharmaceutical company chose to partner with Labcorp to provide central laboratory testing services for a complex regional clinical trial. Their flow cytometry (FCM) panel for immunology was planned for a duration of three to four years. The primary challenges were the short stability period (48 hours) of trial samples and the fact that all the trial locations were not yet determined. Labcorp’s efficient logistics enabled speedy shipping for reliable data. By leveraging its worldwide network of accredited central lab facilities that use standardized assays and procedures, Labcorp gave the client the flexibility to conduct trials wherever needed, while ensuring consistent and reliable data that was also combinable.

Labcorp to Announce First Quarter Financial Results on April 25, 2024

BURLINGTON, N.C. , March 27, 2024 /PRNewswire/ --  Labcorp  (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the first quarter of 2024 before the market opens on Thursday, April 25, 2024 .

The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results for Patients with Non-Small Cell Lung Cancer

Labcorp Launches pTau217 Blood Biomarker Test to Accelerate Path to Diagnosis of Alzheimer's Disease and Support Clinical Trials

Addition of pTau217 test further expands the company's leadership in testing options for Alzheimer's disease to improve patient care  BURLINGTON, N.C. , March 20, 2024 /PRNewswire/ -- Labcorp  (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the

Stage 4 at 34: A woman’s journey from early-onset colon cancer to patient advocacy

After facing early-onset colon cancer, Bridgette is sharing her story of her first colon cancer symptoms and raising awareness of early colon cancer screening.

Labcorp Presents New Research Demonstrating Clinical Impact of Precision Diagnostics in Guiding Biomarker-targeted Therapies for Patients with Epithelial Ovarian Cancer

Outcomes point to value of biomarker testing in addressing testing gaps in clinical practice BURLINGTON, N.C. , March 16, 2024 /PRNewswire/ -- Labcorp  (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today presented the results from two studies at the 2024 SGO